Don't Know Much About Health Care and Public Health... but Appointed to Leadership Positions in US Government Health Care Agencies
Discussion Again, it stands to reason that people entrusted with running US government health care, public health and health policy should have some level of knowledge of biomedical science, health care, public health and/or health policy. I dimly remember that before the Trump administration, many such leaders did have such background. Not any more.This is only the latest examples of amazingly ill-informed people taking important responsibilities in government agencies having to do with health care, public health, and/or health policy. Remember the brew-master with power over major policies in the V...
Source: Health Care Renewal - April 5, 2018 Category: Health Management Tags: DHHS Donald Trump ill-informed management narcotics Source Type: blogs
How Do We Counter Health Care Disinformation Under a Disinformer-in-Chief?
DiscussionAn international organization, Cambridge Analytica/ SCL based in the UK, led by Trump confidantes including his last campaign leader and former White House strategic adviser Steve Bannon, and major Republican donors and hedge fund magnates Robert and Rebekah Mercer, worked with the Trump 2016 campaign, particularly coordinating with digital coordinator Brad Parscale. Cambridge Analytica/ SCL leveraged Facebook private data on millions of people, obtained from most without their specific permission, to create a " psyops " political disinformation campaign featuring emotional appeals to voters ' internal psyc...
Source: Health Care Renewal - March 28, 2018 Category: Health Management Tags: crime disinformation Donald Trump extortion propaganda stealth health policy advocacy stealth lobbying stealth marketing Source Type: blogs
Top 12 Companies Bringing Blockchain To Healthcare
Security, trust, traceability, and control – these are the promises of the blockchain, the technology with the most potential in healthcare at the moment. As these are highly attractive traits for storing sensitive health data or for the operation of supply chains, many companies aim to leverage its powers for healthcare. We collected the most promising enterprises here.
The buzzword of the year award goes to blockchain
It would be a big surprise if the buzzword of the year award would not go to blockchain in 2018. Although the technology is indeed a game-changer, the craze and hype around it remind some experts of the d...
Source: The Medical Futurist - March 27, 2018 Category: Information Technology Authors: nora Tags: Security & Privacy AI artificial intelligence big data blockchain future genetics genomics Health health data health IT health market Innovation Personalized medicine Source Type: blogs
The Other Opioid Crisis: Hospital Shortages Lead To Patient Pain, Medical Error
I came across this public-accesss story, and wanted to share the perspective:
Pauline Bartolone, Kaiser Health News
Even as opioids flood American communities and fuel widespread addiction, hospitals are facing a dangerous shortage of the powerful painkillers needed by patients in acute pain, according to doctors, pharmacists and a coalition of health groups.
The shortage, though more significant in some places than others, has left many hospitals and surgical centers scrambling to find enough injectable morphine, Dilaudid and fentanyl — drugs given to patients undergoing surgery, fighting cancer or suffering traumatic i...
Source: Suboxone Talk Zone - March 26, 2018 Category: Addiction Authors: Jeffrey Junig MD PhD Tags: Acute Pain Anesthesia Public policy surgery Chronic pain opioid addiction Source Type: blogs
The Other Opioid Crisis: Hospital Shortages Lead To Patient Pain, Medical Error
I came across this public-accesss story, and wanted to share the perspective:
Pauline Bartolone, Kaiser Health News
Even as opioids flood American communities and fuel widespread addiction, hospitals are facing a dangerous shortage of the powerful painkillers needed by patients in acute pain, according to doctors, pharmacists and a coalition of health groups.
The shortage, though more significant in some places than others, has left many hospitals and surgical centers scrambling to find enough injectable morphine, Dilaudid and fentanyl — drugs given to patients undergoing surgery, fighting cancer or suffering traumatic i...
Source: Suboxone Talk Zone - March 26, 2018 Category: Addiction Authors: admin Tags: Acute Pain Anesthesia Public policy surgery Chronic pain opioid addiction Source Type: blogs
The Other Opioid Crisis: Hospital Shortages Lead To Patient Pain, Medical Error
I came across this public-accesss story, and wanted to share the perspective:
Pauline Bartolone, Kaiser Health News
Even as opioids flood American communities and fuel widespread addiction, hospitals are facing a dangerous shortage of the powerful painkillers needed by patients in acute pain, according to doctors, pharmacists and a coalition of health groups.
The shortage, though more significant in some places than others, has left many hospitals and surgical centers scrambling to find enough injectable morphine, Dilaudid and fentanyl — drugs given to patients undergoing surgery, fighting cancer or suffering traumatic i...
Source: Suboxone Talk Zone - March 26, 2018 Category: Addiction Authors: admin Tags: Acute Pain Anesthesia Public policy surgery Chronic pain opioid addiction Source Type: blogs
Blockchain Technology for Transparent Drug Pricing: Interview with Cambridge Consultants
Frustration with the US pharmaceutical industry has been on the rise along with the steadily increasing out-of-pocket copays for prescriptions drugs. The news cycle has also been reporting more frequently on extreme overnight price hikes on, at times, life-saving drugs. Many people are suspecting foul play because drug price negotiations are often held behind closed doors. Together, these factors have increased the average American’s mistrust of “Big Pharma”.
What could the pharmaceutical industry do to rebuild trust and improve the public perception of the sector? Can cutting-edge technology be utilized to make dr...
Source: Medgadget - March 19, 2018 Category: Medical Devices Authors: Mohammad Saleh Tags: Exclusive Public Health Society Source Type: blogs
Hospitalized Patients Are Civilian Casualties in the Government's War on Opioids
A recentstory by Pauline Bartolone in the Los Angeles Times draws attention to some under-reported civilian casualties in the government ’s war on opioids: hospitalized patients in severe pain, in need of painkillers. Hospitals across the country are facing shortages of injectable morphine, fentanyl, and Dilaudid (hydromorphone). As a result, trauma patients, post-surgical patients, and hospitalized cancer patients frequently go un dertreated for excruciating pain.Hospitals, including the ones in which I practice general surgery, are working hard to ameliorate the situation by asking medical staff to use prescription opi...
Source: Cato-at-liberty - March 18, 2018 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs
Interview with Devyn Smith PhD, COO of Sigilon Therapeutics
Sigilon Therapeutics is a Cambridge, MA-based biotech company developing innovative therapeutics by encapsulating cells in a novel coating that renders them invisible to the immune system. The engineered cells contained in the company’s particles can provide long-term continuous therapy for a range of chronic disorders, including hemophilia and diabetes, and eliminate the need for intermittent injection or infusion. With this technological breakthrough Sigilon hopes to “fundamentally change the trajectory of disease treatment.”
Medgadget editor Tom Peach recently spoke with Devyn Smith PhD, Chief Strategy Officer of ...
Source: Medgadget - March 13, 2018 Category: Medical Devices Authors: Tom Peach Tags: Exclusive Genetics Materials Medicine Pediatrics Source Type: blogs
The NIH starts spending $1.5 billion in new Brain Research through Advancing Innovative Neuro-technologies (BRAIN) projects
___
NIH Starts to Spend $4.8 Billion in “Extra” Cures Drug Research Money (P&T Community):
“The National Institutes of Health (NIH) launched 110 new brain research projects in the fiscal year ending last September (2017) with the first portion of the $1.5 billion over 10 years it will hopefully receive from the 21st Century Cures Act, which spread a total of $4.8 billion over four NIH programs. That is money over and above the NIH annual appropriation from Congress. The other three “Innovation Funds” are: Precision Medicine, Cancer Moonshot, and Regenerative Medicine.
The $1.5 billion in new Brain Research th...
Source: SharpBrains - March 7, 2018 Category: Neuroscience Authors: SharpBrains Tags: Cognitive Neuroscience Health & Wellness Technology Alzheimers brain clinical-trials Innovation Funds Moonshot National-Institutes-of-Health Neuro-technologies neurotechnologies NIH Pfizer Source Type: blogs
A Health Tech ’s Secret Weapon: The People Under The Hood
By DAVID SHAYWITZ, MD
The recently-announced acquisition of the oncology data company Flatiron Health by Roche for $2.1B represents a robust validation of the much-discussed but infrequently-realized hypothesis that technology entrepreneurs who can turn health data into actionable insights can capture significant value for this accomplishment.
Four questions underlying this deal (a transaction first reported, as usual, by Chrissy Farr) are: (1) What is the Flatiron business model? (2) What makes Flatiron different from other health data companies? (3) Why did Roche pay so much for this asset? (4) What are the lessons ot...
Source: The Health Care Blog - February 20, 2018 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized David Shaywitz Flatiron Health Human Oncology Source Type: blogs
Alzheimer ’s Drug Solanezumab Fails in Phase 3 Clinical Trial
This study was the first major Alzheimer ’s clinical trial to require molecular evidence of amyloid deposition in the brain for enrollment. While the treatment did have some favorable effects, in the main measure of outcome — measured with a cognitive test called the Alzheimer’s Disease Assessment Scale-cognitive subscale —the researchers did not observe any statistically significant benefit compared with placebo.One Good Reason To Consider an Alzheimer's Clinical TrialThe authors suggest that while it is not certain that this particular strategy or drug could be effective, it is possible that either not enough dru...
Source: Alzheimer's Reading Room, The - January 25, 2018 Category: Neurology Tags: alzheimers clinical tiral alzheimers symptoms clinical trial news solanezumab Source Type: blogs
With pharma exiting Alzheimer ’s research, new hope (and urgency) seen in the combination of brain training and transcranial direct current stimulation (tDCS)
This study is examining the combination of two novel interventions – transcranial direct current stimulation (tDCS) and cognitive remediation therapy – to protect against AD in patients with depression or mild cognitive impairment. The study is funded by Brain Canada and carried out by researchers in CAMH’s Geriatric Psychiatry Division in collaboration with Baycrest, St. Michael’s Hospital, Sunnybrook Health Sciences Centre and University Health Network.
The Study in Context
Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
Important insights on the growing home use of tDCS brain stimulati...
Source: SharpBrains - January 22, 2018 Category: Neuroscience Authors: SharpBrains Tags: Cognitive Neuroscience Health & Wellness Technology Alzheimers brain Brain-Fitness Brain-Training brain-training-exercises cognitive remediation cognitive-reserve dementia electrical stimulation mental-exercises Pfizer pharmace Source Type: blogs
Ryan Bourne: Corporate Tax Cut will Help Workers and Shareholders
In case you missed it over the weekend, Cato scholarRyan Bourne wrote about the Republican tax reform plan in an op-ed featured inThe Hill. He responds to the argument that corporations will use money saved from the reduction in the federal corporate tax rate to increase dividends, buy back shares, or other strategies that benefit their shareholders. Major companies, including Cisco Systems, Pfizer and Coca-Cola, have said they will use most of the gains from proposed corporate rate cuts to increase dividends to shareholders or buy back their own shares. This has been reported and shared on Twitter as a slam dunk aga...
Source: Cato-at-liberty - December 4, 2017 Category: American Health Authors: Cato Editors Source Type: blogs
One Barely Noticed Settlement by Pfizer Suggests the Futility of Polite Protests about Health Policy
A few days ago we noticed just one more marcher in theparade of legal settlements. But it was once again a huge health care corporation, and it had aspects that demanded attention.Pfizer Makes $94 Million Settlement of Allegations of Fraud to Delay Generic CompetitionA tinyitem in Becker ' s Hospital News on November 28, 2017, stated:Pfizer will pay $94 million to resolve allegations that it used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex.The lawsuit, brought by 32 direct purchasers of Celebrex in April and certified a class action lawsuit in August, claimed Pfizer attempt...
Source: Health Care Renewal - December 3, 2017 Category: Health Management Tags: adverse effects Celebrex deception impunity legal settlements Pfizer restraint of competition Source Type: blogs
